Guillaume Berton , Bochra Sedaki , Erwann Collomb , Sami Benachour , Michael Loschi , Bilal Mohty , Colombe Saillard , Yosr Hicheri , Camille Rouzaud , Valerio Maisano , Ferdinand Villetard , Evelyne D.'Incan Corda , Aude Charbonnier , Jerome Rey , Marie-Anne Hospital , Antoine Ittel , Norman Abbou , Raphaelle Fanciullino , Bérengère Dadone-Montaudié , Norbert Vey , Sylvain Garciaz
{"title":"Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia","authors":"Guillaume Berton , Bochra Sedaki , Erwann Collomb , Sami Benachour , Michael Loschi , Bilal Mohty , Colombe Saillard , Yosr Hicheri , Camille Rouzaud , Valerio Maisano , Ferdinand Villetard , Evelyne D.'Incan Corda , Aude Charbonnier , Jerome Rey , Marie-Anne Hospital , Antoine Ittel , Norman Abbou , Raphaelle Fanciullino , Bérengère Dadone-Montaudié , Norbert Vey , Sylvain Garciaz","doi":"10.1016/j.leukres.2024.107500","DOIUrl":null,"url":null,"abstract":"<div><p>Mutations in spliceosome genes (<em>SRSF2</em>, <em>SF3B1</em>, <em>U2AF1</em>, <em>ZRSR2)</em> correlate with inferior outcomes in patients treated with intensive chemotherapy for Acute Myeloid Leukemia. However, their prognostic impact in patients treated with less intensive protocols is not well known. This study aimed to evaluate the impact of Spliceosome mutations in patients treated with Venetoclax and Azacitidine for newly diagnosed AML. 117 patients treated in 3 different hospitals were included in the analysis. 34 harbored a mutation in at least one of the spliceosome genes (splice-mut cohort). K/NRAS mutations were more frequent in the splice-mut cohort (47% vs 19%, p=0.0022). Response rates did not differ between splice-mut and splice-wt cohorts. With a median follow-up of 15 months, splice mutations were associated with a lower 18-month LFS (p=0.0045). When analyzing splice mutations separately, we found SRSF2 mutations to be associated with poorer outcomes (p=0.034 and p=0.037 for OS and LFS respectively). This negative prognostic impact remained true in our multivariate analysis. We believe this finding should warrant further studies aimed at overcoming this negative impact.</p></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"141 ","pages":"Article 107500"},"PeriodicalIF":2.1000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0145212624000663/pdfft?md5=4d4e114f1e8bcfb3607ca62b5c9babbc&pid=1-s2.0-S0145212624000663-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0145212624000663","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mutations in spliceosome genes (SRSF2, SF3B1, U2AF1, ZRSR2) correlate with inferior outcomes in patients treated with intensive chemotherapy for Acute Myeloid Leukemia. However, their prognostic impact in patients treated with less intensive protocols is not well known. This study aimed to evaluate the impact of Spliceosome mutations in patients treated with Venetoclax and Azacitidine for newly diagnosed AML. 117 patients treated in 3 different hospitals were included in the analysis. 34 harbored a mutation in at least one of the spliceosome genes (splice-mut cohort). K/NRAS mutations were more frequent in the splice-mut cohort (47% vs 19%, p=0.0022). Response rates did not differ between splice-mut and splice-wt cohorts. With a median follow-up of 15 months, splice mutations were associated with a lower 18-month LFS (p=0.0045). When analyzing splice mutations separately, we found SRSF2 mutations to be associated with poorer outcomes (p=0.034 and p=0.037 for OS and LFS respectively). This negative prognostic impact remained true in our multivariate analysis. We believe this finding should warrant further studies aimed at overcoming this negative impact.
期刊介绍:
Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.